One-year results from the ADALA trial

Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.

The study compared three months of low-dose DOAC with three months of DAPT followed by aspirin, assessing a composite endpoint that included device-related thrombosis, clinical thromboembolic events, and major bleeding.

Low-dose DOAC was associated with a lower rate of this composite outcome, driven mainly by a clear reduction in bleeding while maintaining efficacy.

These findings could influence future antithrombotic strategies after LAA closure. Hit play to discover the full discussion!

This interview was filmed at PCR London Valves 2025: see more videos here.